Skip to main content
An official website of the United States government

Pre-Cancer Atlas (PCA)

A tumor (yellow) is shown in the background. Components within the microenvironment are overlaid on the tumor, including a dendritic cell (pink), a T-cell (blue), a fibroblast (purple and pink), a natural killer cell (dark blue), a regulatory t cell (aqua), blood vessels (red), a macrophage cell (red with a yellow center), and a myeloid cell (green).

The Pre-cancer Atlas (PCA) Research Centers are part of the Human Tumor Atlas Network (HTAN). HTAN, an NCI-collaborative program, is constructing multi-dimensional atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments over time.

The atlases being created by HTAN describe important changes during cancer progression, such as the transition of precancers to malignant tumors, the evolution of metastatic cancer, and the development of treatment resistance.

HTAN is supported by the NCI Division of Cancer Prevention (DCP), NCI Division of Biology (DCB), the NCI Division of Cancer Treatment and Diagnosis (DCTD), and the NCI Center for Strategic Science Initiatives (CSSI).

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

About Pre-Cancer Atlas

The Pre-cancer Atlas (PCA) Research Centers, along with the Human Tumor Atlas (HTA) Research Centers and a Data Coordinating Center (DCC), make up HTAN. Each PCA Research Center will create a 2D/3D precancer atlas of a pre-cancerous lesion, focusing on how it changes into cancer.

PCA Research Centers have three major tasks:

  • Collecting, processing, and labeling biospecimens.
  • Studying the molecular, cellular, and spatial details of the lesions.
  • Analyzing and modeling the data.

PCA Research Centers will collaborate with other components of HTAN to make the data and analytical tools available to the research community.

Grantee Details

PI Name Sort descending PI Organization Title Grant Number Program Official
Baghdadi, Tareq Al

Saint Joseph Mercy Health System
United States

Michigan Cancer Research Consortium NCORP 3UG1CA189971-11S1 Vanessa A. White, M.P.H.
Balaj, Leonora

Massachusetts General Hospital
United States

Standardized Molecular Analyses of Glioma EVs 5R01CA237500-05 Matthew Young, Ph.D.
Balskus, Emily Patricia

Harvard University
United States

PROSPECT: Pathways, Risk factors, and mOleculeS to Prevent Early-onset Colorectal Tumors 3OT2CA297577-01S1 Asad Umar, D.V.M., Ph.D.
Balu, Mihaela

University Of California-Irvine
United States

Fast, large area, multiphoton exoscope (FLAME) for improving early detection of melanoma 4R01CA259019-04 Guillermo Marquez, Ph.D.
Banerjee, Imon

Mayo Clinic Arizona
United States

Multimodal AI Fusion Model for Early Detection for Pancreatic Cancer 5R01CA289249-02 Nicholas Hodges, Ph.D.
Bao, Ting

Dana-Farber Cancer Inst
United States

Acupuncture for Chemothrapy-induced Peripheral Neuropathy Treatment (ACT) Trial 5R37CA248563-05 Asad Umar, D.V.M., Ph.D.
Bao, Ting

Dana-Farber Cancer Inst
United States

Acupuncture for Chemothrapy-induced Peripheral Neuropathy Treatment (ACT) Trial 5R37CA248563-05 Asad Umar, D.V.M., Ph.D.
Bao, Ting

Dana-Farber Cancer Inst
United States

Acupuncture for Chemothrapy-induced Peripheral Neuropathy Treatment (ACT) Trial 5R37CA248563-05 Asad Umar, D.V.M., Ph.D.
Bao, Ting

Dana-Farber Cancer Inst
United States

Yoga for Chemotherapy-induced Peripheral Neuropathy Treatment (YCT) Trial 5R01CA251470-06 Goli Samimi, Ph.D., M.P.H.
Bao, Ting

Dana-Farber Cancer Inst
United States

Yoga for Chemotherapy-induced Peripheral Neuropathy Treatment (YCT) Trial 5R01CA251470-06 Goli Samimi, Ph.D., M.P.H.
Bao, Ting

Dana-Farber Cancer Inst
United States

Yoga for Chemotherapy-induced Peripheral Neuropathy Treatment (YCT) Trial 5R01CA251470-06 Goli Samimi, Ph.D., M.P.H.
Barber, Glen N.

Ohio State University
United States

Development of A HTLV-1 Vaccine 7R01CA252049-05 Marjorie Perloff, M.D.
Barroilhet, Lisa M

University Of Wisconsin-Madison
United States

Repurposing Atovaquone for Preventing Ovarian Cancer: An Example of Successful Inhibition of Oxidative Phosphorylation 5R01CA238423-05 Goli Samimi, Ph.D., M.P.H.
Barroilhet, Lisa M

University Of Wisconsin-Madison
United States

The MW Cancer Prevention Clinical Trials Network 5UG1CA242635-05 Donald Johnsey
Bartolini, Francesca

Columbia University Health Sciences
United States

Investigating the Pathogenic Role of Tubulin Post-translational Modifications in CIPN 5R01CA279401-02 Rachel Altshuler, Ph.D.